ECX (epirubicin-CISplatin-capecitabine)*

*drug in italics is IV drug given in hospital or cancer centre

Diagnosis: Gastroesophageal Cancer

Clinical Verification

☐ Bloodwork and other clinical parameters have been verified by a regulated health professional

☐ Prescription has been verified by a nurse or pharmacist

Rx (Start Date/Day 1: __________)

capcitabine 625 mg/m² x BSA x ____% dose* = ________ mg PO BID with meals on Days 1 to 21

Mitte: _____ x 500 mg tablets and _____ x 150 mg tablets (_____ days supply)

No LU Code for this indication  NO Repeats

*Dose modification for: ☐ Age/performance status ☐ Hepatic function ☐ Renal function ☐ Other: __________

Supportive Care Rx

☐ aprepitant 125 mg PO pre-chemotherapy on Day 1 THEN 80 mg PO daily on Days 2 and 3

Mitte: ____ Repeat: _____ LU Code_____

☐ 5-HT₃ receptor antagonist (centre choice) pre-chemotherapy on Day 1

Mitte: ____ Repeat: _____ LU Code_____

☐ dexamethasone 12 mg PO pre-chemotherapy on Day 1 THEN 8 mg PO daily on Days 2, 3, 4

Mitte: ____ Repeat: _____

☐ prochlorperazine 10 mg PO q6h PRN nausea  Mitte: ____ Repeat: _____

☐ loperamide 4 mg at the first sign of diarrhea, then 2 mg after every loose bowel movement PRN

Mitte: ____ Repeat: _____ LU Code 113

Allergies (also specify reaction) ☐ None known

Patient Name _________________________________________

Allergies (also specify reaction) ☐ None known

Patient Name _________________________________________

Page 1 of 2

Developed by the Drug Formulary Team at Cancer Care Ontario.
Format and content have been adapted with permission from Mount Sinai Hospital
ECX - Version 1.0
OPTIONAL INFORMATION

☐ Patient has been counseled by an Oncology Pharmacist


Print name ____________________________________________________________________________ Signature ____________________________________________________________________________ Date ____________________________________________________________________________

OR

☐ Requires counseling

☐ Drug interaction assessment

Drug-specific information

For the complete information, please refer to the Cancer Care Ontario drug information sheets available at www.cancercare.on.ca/drugformulary